The US Food and Drug Administration (USFDA) has issued an EIR for the company's manufacturing facility located at Baddi, Himachal Pradesh, Alkem Laboratories said in a regulatory filing.
The USFDA had inspected the plant from September 11, 2017 to September 15, 2017.
The company said it had submitted a detailed corrective and preventive action (CAPA) plan to the USFDA within the stipulated time lines in response to the two Form 483 observations issued by the regulator.
USFDA releases a copy of the EIR to the establishment that is subject of an FDA or FDA-contracted inspection when the agency determines the same to be closed.
Alkem shares today ended 5.74 per cent higher at Rs 2,347.70 apiece on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content